Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

1997

Summary Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Many treatments have been proposed but considerable uncertainty still remains about their effectiveness. In this review we evaluated the quality, clinical coherence, consistency and results of Randomized Controlled Trials (RCT) of non-surgical treatments for HCC. Methods Thirty-seven RCTs examining the effect of different treatments were retrieved using MEDLINE (November 1978 to December 1995) and a review of reference lists. Selected aspects of the quality of design, conduct and reporting were examined. The odds ratio for the probability of surviving up to one year was calculated according to the …

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentlaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansEmbolizationRandomized Controlled Trials as Topicbusiness.industryArterial EmbolizationLiver NeoplasmsHematologyOdds ratioEmbolization TherapeuticChemotherapy regimenSurgeryClinical trialClinical Trials Phase III as TopicOncologyMeta-analysisImmunotherapybusinessAnnals of Oncology
researchProduct

Testing the water before swimming: satisfying the need for clinical trials of devices, media, and instruments before their use in assisted reproducti…

2011

Malemedicine.medical_specialtyClinical Trials as TopicReproductive Techniques Assistedbusiness.industryClinical Laboratory TechniquesReproduction (economics)Patient SelectionObstetrics and GynecologyEquipment DesignRisk AssessmentCulture MediaClinical trialReproductive MedicineInfertilityMaterials TestingMedicineHumansMedical physicsFemaleDiffusion of InnovationPeriodicals as TopicbusinessEditorial PoliciesFertility and sterility
researchProduct

Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations.

2021

Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent…

Malemedicine.medical_specialtyClinical trial protocols as topicmedicine.medical_treatmentPsychological intervention030204 cardiovascular system & hematologySubspecialtylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPhysiology (medical)MedicineHumansMedical physics030212 general & internal medicineCoronary VesselClinical Trials as TopicInterventional cardiologybusiness.industryClinical study designPercutaneous coronary interventionCoronary VesselsCoronary OcclusionCoronary occlusionEndpoint determination:Myocardial revascularizationObservational studyFemaleCardiology and Cardiovascular MedicinebusinessCirculation
researchProduct

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

2011

We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had β2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete respo…

Malemedicine.medical_specialtyCyclophosphamideClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologyMedizinNeutropeniaOfatumumabAntibodies Monoclonal HumanizedBiochemistryGastroenterologychemistry.chemical_compoundChemoimmunotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideCD20Chlorambucilbiologybusiness.industryAntibodies MonoclonalCell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellNeoadjuvant TherapySurgeryFludarabineTreatment Outcomechemistrybiology.proteinFemaleImmunotherapybusinessVidarabinemedicine.drug
researchProduct

Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease …

1984

The effect of a 3 month daily administration of 800 mg pentoxifylline (Trental 400 bds) or placebo was assessed under double blind crossover design in 18 patients (12 males and 6 females) with peripheral occlusive arterial disease in respect of painfree walking distance and various hemorheological and hemostasiological variables, platelet aggregation, serum cholesterol and triglycerides. In first treatment period walking distance significantly increased with pentoxifylline by 46% from baseline 121 ± 15 m and by 4% with placebo from baseline 134 ± 18 m. Pentoxifylline administration furthermore yielded significant decrease in whole blood and plasma viscosity and significant increase in eryt…

Malemedicine.medical_specialtyErythrocytesPlatelet Aggregationmedicine.medical_treatment030204 cardiovascular system & hematologyPlaceboPentoxifyllineDouble blindPlacebos03 medical and health sciences0302 clinical medicineDouble-Blind MethodMedicineHumansIn patient030212 general & internal medicineClinical efficacyPentoxifyllineTriglyceridesAgedChemotherapyClinical Trials as Topicbusiness.industryOcclusive arterial diseaseIntermittent ClaudicationMiddle AgedBlood ViscosityCrossover studySurgeryAdenosine DiphosphateCholesterolAnesthesiaTheobromineFemaleCollagenCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAngiology
researchProduct

Management of pre-malignant and malignant lesions by endoscopic resection

2003

Endoscopic resection (ER) has gained more and more importance in the treatment of early gastrointestinal neoplasia over the last few years. The choice of the different available techniques depends on the site, the macroscopic type of the tumour and the personal experience of the endoscopist. The 'suck-and-cut' technique with ligation device or cap should be favoured to normal strip biopsy in the oesophagus because of the size of the resected specimen and its technical feasibility. A recently described method of ER in the stomach is the circumferential mucosal incision with a type of needle-knife and subsequent en-bloc resection following prior injection under the lesions. ER of high-grade i…

Malemedicine.medical_specialtyEsophageal NeoplasmsColorectal cancerEndoscopic mucosal resectionRisk AssessmentBarrett EsophagusStomach NeoplasmsmedicineHumansMinimally Invasive Surgical ProceduresGastrointestinal NeoplasmsNeoplasm StagingClinical Trials as TopicIntraepithelial neoplasiamedicine.diagnostic_testbusiness.industryStomachBiopsy NeedleGastroenterologyEndoscopymedicine.diseaseImmunohistochemistrydigestive system diseasesEndoscopySurgeryMajor duodenal papillaTreatment Outcomemedicine.anatomical_structureAdenocarcinomaFemaleLigationbusinessPrecancerous ConditionsFollow-Up StudiesBest Practice & Research Clinical Gastroenterology
researchProduct

The Oxidative Stress Concept of Nitrate Tolerance and the Antioxidant Properties of Hydralazine

2005

The hemodynamic and anti-ischemic effects of nitroglycerin (NTG) are rapidly blunted as a result of the development of nitrate tolerance. With initiation of NTG therapy, it is possible to detect neurohormonal activation and intravascular volume expansion. These so-called pseudotolerance mechanisms may compromise the vasodilatory effects of NTG. Long-term nitrate treatment also is associated with decreased vascular responsiveness caused by changes in intrinsic mechanisms of the tolerant vasculature itself. According to the oxidative stress concept, increased vascular superoxide (O 2 − ) production and an increased sensitivity to vasoconstrictors secondary to activation of protein kinase C co…

Malemedicine.medical_specialtyMaximum Tolerated Dosegenetic structuresDrug ResistanceMyocardial IschemiaPharmacologyCoronary Angiographymedicine.disease_causeSeverity of Illness IndexDrug Administration ScheduleNitric oxideNitroglycerinchemistry.chemical_compoundInternal medicinemedicineAnimalsHumansDrug Interactionschemistry.chemical_classificationClinical Trials as TopicReactive oxygen speciesDose-Response Relationship Drugbusiness.industryHydralazineHydralazineLong-Term Careeye diseasesDisease Models AnimalOxidative StresschemistryHeart Function TestsExercise TestCardiologyFemaleVascular ResistanceEndothelium Vascularsense organsSodium nitroprussideCardiology and Cardiovascular MedicineSoluble guanylyl cyclasebusinessNicotinamide adenine dinucleotide phosphatePeroxynitriteOxidative stressmedicine.drugThe American Journal of Cardiology
researchProduct

Mediterranean diet and heart rate: the PREDIMED randomised trial

2014

A higher heart rate (HR) has been associated with increased total and cardiovascular mortality [1] and [2]. Clinical trials support the beneficial effect of decreasing HR in patients with heart failure [3] and ischaemic heart disease [4]. A recent cross-sectional study showed that closer adherence to the Mediterranean diet (MeDiet) was related to lower HR [5]. We evaluated the association between adherence to the MeDiet (measured with a score from 0 to 14 obtained by a validated screener [6]) and HR using both a cross-sectional and a longitudinal analysis of the PREDIMED trial [7] and [8].

Malemedicine.medical_specialtyMediterranean dietHeart rateDiet MediterraneanDiabetes ComplicationsClinical trialsHeart RateMediterranean dietMedicineHumansSocioeconomicsAgedSistema cardiovascularAged 80 and overCorazónbusiness.industryMiddle AgedPredimedSurgeryClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesChristian ministryFemaleDietaCardiology and Cardiovascular MedicinebusinessOlive oil
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

1980

Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression o…

Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessBritish journal of urology
researchProduct